What formulation, quality, regulatory, and procurement teams should consider when selecting and qualifying gelatin for pharmaceutical products.
Why Gelatin Is an Established Pharmaceutical Excipient
Gelatin has been used in medicines for over a century, and for good reason. It is biologically derived, generally recognized as safe, flexible across dosage forms, and compatible with a wide range of active pharmaceutical ingredients (APIs). As a pharmaceutical excipient, it appears in hard capsules, softgels, tablet coatings, suppositories, and even as a plasma expander and wound-care matrix.
The Functional Roles Gelatin Plays
A single excipient can carry several jobs in one formulation, which is precisely why buyers value it:
- Capsule shell formation: gelatin’s thermoreversible gelation and film-forming properties support the manufacture of two-piece hard capsule shells and plasticized softgel shells.
- Binding and cohesion: gelatin solutions can be used as binders in selected tablet formulations to support granule formation and mechanical strength.
- Film coating: gelatin can be used in certain traditional or specialized tablet-coating formulations.
- Stabilization: in liquids and semi-solids, gelatin suspends particles and improves mouthfeel or viscosity.
- Biocompatibility: in advanced applications, it serves as a degradable matrix for controlled delivery.
What “Pharmaceutical Grade” Should Demonstrate
The proposed material should meet the applicable pharmacopoeial monograph and the customer’s approved specification, be manufactured under an appropriate quality system, and be supported by supplier qualification and lot-specific release data. Because requirements vary by market, dosage form, and route of administration, “pharmaceutical grade” should be verified through documented controls rather than accepted as a marketing label.
QA should be able to link each received lot to an approved material specification, supplier identity, lot-specific COA, qualification status, and any required animal-origin or TSE documentation. The supplier’s internal batch records are normally maintained within its quality system and may be reviewed through qualification or audit where appropriate.
Safety Profile Buyers Should Understand
The suitability of pharmaceutical gelatin depends on its intended use and the controls applied throughout the supply chain. Buyers and drug-product manufacturers should identify the material attributes and impurity risks that are relevant to the dosage form, route of administration, formulation, and destination market:
- Microbiological quality: establish microbial limits appropriate to the material and intended use. Bacterial-endotoxin testing may be necessary for certain parenteral or otherwise high-risk applications, but it is not automatically required for every oral gelatin grade.
- Elemental impurities: evaluate relevant elemental-impurity risks through the applicable pharmacopoeial requirements, supplier information, manufacturing process, and finished-drug risk assessment.
- Animal origin and TSE risk: document the animal species, tissues, countries of origin, manufacturing process, traceability, and applicable TSE controls.
- Process-related impurities: assess substances that could reasonably arise from the raw materials or manufacturing process and apply the relevant specification and test requirements.
- Performance-related properties: control gel strength, viscosity, moisture, pH, clarity, particle size, or other attributes according to their effect on the intended formulation and process.
BSE/TSE Documentation for Animal-Derived Gelatin
For gelatin derived from bovine or other TSE-relevant materials, the assessment should consider the animal species, tissues used, countries of origin, traceability, and manufacturing process. Buyers should request the animal-origin and TSE documentation required for the destination market and intended drug product. In the European context, a valid TSE Certificate of Suitability may support compliance with the relevant Ph. Eur. TSE requirements, but it does not replace the COA or demonstrate batch-specific quality compliance.
Regulatory Pathways and Documentation
Pharmaceutical gelatin qualification should be supported by documents that allow the customer to evaluate material quality, animal origin, manufacturing controls, traceability, and change management. The required package depends on the destination market, dosage form, route of administration, and the customer’s supplier-qualification procedure. No single certificate replaces a complete, risk-based assessment.
| Document | Why it matters |
|---|---|
| Certificate of Analysis (CoA) | Batch-specific data: gel strength, viscosity, microbials, heavy metals. |
| Quality-system information | Supports supplier qualification through relevant certificates, questionnaires, audits, quality agreements, and change-notification procedures. |
| Animal-origin and TSE documentation | Describes the animal source, tissue, origin, traceability, process, and applicable TSE controls. |
| Pharmacopeial compliance | Identifies the applicable monograph, agreed limits, test methods, and any additional customer requirements. |
| Stability / retestdata | Supports the gelatin’s storage conditions and retest or expiry period. |
Matching Grade to Application
Pharmaceutical gelatin should be selected according to its intended function and process. For hard capsule shells, gel strength, viscosity, setting behaviour, clarity, colour, microbiological quality, and performance on the capsule line may all be relevant. Softgel performance also depends on the complete shell formulation—including gelatin, plasticizer, and water—as well as fill compatibility, encapsulation, sealing, and drying conditions.
Share the dosage form, intended function, manufacturing process, animal-source requirements, destination market, and target material specification with the supplier. The supplier can recommend a candidate grade, but the customer should qualify it in the intended formulation and production process.
Frequently Asked Questions
Q: Can food-grade gelatin be used in pharmaceuticals?
A: Not for drug products. Pharmaceutical applications require GMP manufacture and pharmacopeial release testing that food grade does not provide.
Q: What BSE/TSE evidence should I request?
A: A country-of-origin declaration, a TSE/BSE risk statement, and proof that source animals were fit for human consumption in negligible-risk regions.
Q: Does gelatin affect dissolution rate?
A: Yes. Gel strength and viscosity directly influence capsule dissolution and API release, so grade selection must be application-specific.
Q: How do I verify pharmacopeial compliance?
A: Require a CoA referencing the relevant monograph (USP/EP/JP/ChP) and, where needed, third-party testing against it.
Key Takeaways
- Pharmaceutical gelatin must be GMP-made and released against a pharmacopeial monograph — food grade is not equivalent.
- BSE/TSE documentation and endotoxin/microbial controls are core safety requirements, not extras.
- Grade selection should follow your route of administration and dissolution target, not supplier inventory.
- A true pharma supplier provides a complete regulatory dossier and supply continuity that de-risks your pipeline.
Post time: Sep-09-2026
